Literature DB >> 14700606

Cell-cycle targeted therapies.

Charles Swanton1.   

Abstract

Eukaryotic organisms depend on an intricate and evolutionary conserved cell cycle to control cell division. The cell cycle is regulated by a number of important protein families which are common targets for mutational inactivation or overexpression in human tumours. The cyclin D and E families and their cyclin-dependent kinase partners initiate the phosphorylation of the retinoblastoma tumour suppressor protein and subsequent transition through the cell cycle. Cyclin/cdk activity and therefore control of cell division is restrained by two families of cyclin dependent kinase inhibitors. A greater understanding of the cell cycle has led to the development of a number of compounds with the potential to restore control of cell division in human cancers. This review will introduce the protein families that regulate the cell cycle, their aberrations in malignant progression and pharmacological strategies targeting this important process.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14700606     DOI: 10.1016/s1470-2045(03)01321-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  66 in total

1.  Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies.

Authors:  Glen J Weiss; Manuel Hidalgo; Mitesh J Borad; Daniel Laheru; Raoul Tibes; Ramesh K Ramanathan; Lisa Blaydorn; Gayle Jameson; Antonio Jimeno; Jeffrey D Isaacs; Angela Scaburri; Maria Adele Pacciarini; Francesco Fiorentini; Marina Ciomei; Daniel D Von Hoff
Journal:  Invest New Drugs       Date:  2011-12-09       Impact factor: 3.850

Review 2.  Role of cell cycle proteins in CNS injury.

Authors:  Kimberly R Byrnes; Alan I Faden
Journal:  Neurochem Res       Date:  2007-04-03       Impact factor: 3.996

3.  PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01.

Authors:  Crissy Dudgeon; Peng Wang; Xiameng Sun; Rui Peng; Quanhong Sun; Jian Yu; Lin Zhang
Journal:  Mol Cancer Ther       Date:  2010-10-26       Impact factor: 6.261

Review 4.  The cell cycle: a critical therapeutic target to prevent vascular proliferative disease.

Authors:  Thierry Charron; Nafiseh Nili; Bradley H Strauss
Journal:  Can J Cardiol       Date:  2006-02       Impact factor: 5.223

5.  Chaga mushroom (Inonotus obliquus) induces G0/G1 arrest and apoptosis in human hepatoma HepG2 cells.

Authors:  Myung-Ja Youn; Jin-Kyung Kim; Seong-Yeol Park; Yunha Kim; Se-Jin Kim; Jin-Seok Lee; Kyu-Yun Chai; Hye-Jung Kim; Ming-Xun Cui; Hong-Seob So; Ki-Young Kim; Raekil Park
Journal:  World J Gastroenterol       Date:  2008-01-28       Impact factor: 5.742

Review 6.  Cell cycle activation and spinal cord injury.

Authors:  Junfang Wu; Bogdan A Stoica; Alan I Faden
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

7.  Aberrant cell cycle reentry in human and experimental inclusion body myositis and polymyositis.

Authors:  Bumsup Kwon; Pravir Kumar; Han-Kyu Lee; Ling Zeng; Kenneth Walsh; Qinghao Fu; Amey Barakat; Henry W Querfurth
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

8.  Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer.

Authors:  Evanthia Galanis; Stephanie K Carlson; Nathan R Foster; Val Lowe; Fernando Quevedo; Robert R McWilliams; Axel Grothey; Aminah Jatoi; Steven R Alberts; Joseph Rubin
Journal:  Mol Ther       Date:  2008-03-18       Impact factor: 11.454

9.  PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.

Authors:  Richard S Finn; Judy Dering; Dylan Conklin; Ondrej Kalous; David J Cohen; Amrita J Desai; Charles Ginther; Mohammad Atefi; Isan Chen; Camilla Fowst; Gerret Los; Dennis J Slamon
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

10.  Smoothened as a new therapeutic target for human osteosarcoma.

Authors:  Masataka Hirotsu; Takao Setoguchi; Hiromi Sasaki; Yukihiro Matsunoshita; Hui Gao; Hiroko Nagao; Osamu Kunigou; Setsuro Komiya
Journal:  Mol Cancer       Date:  2010-01-12       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.